Peloton’s turmoil could be appealing
FT News Briefing
00:00
Intro
This chapter examines the financial struggles of biotech companies as investors pull back their funds amid a downturn in the market. It highlights the challenges of long drug development timelines and a growing preference among investors for safer investment options.
Play episode from 00:00
Transcript
